Certain biologics raise infection risk in patients with psoriasis: study
French real-world data highlights differences even between biologics of the same class.
Patients with psoriasis who are new users of infliximab and adalimumab may be at greater risk of serious infection than those beginning therapy with etanercept, an observational study shows.
In a study of 44,000 French patients with psoriasis who initiated biologics or apremilast between 2008 and 2019, researchers aimed to determine the comparative safety of the agents in the real world.
They noted the fast emergence of new therapeutics in psoriasis and that clinical trials were not adequately powered to assess the risk of infection leading to hospitalisation.
The mean age of patients in the study was 48 years and median follow-up was for 12 months.
